When Both Tumour-Infiltrating Lymphocytes and Gene Expression are Available, the Prognostic and Predictive Value of RNA Sequencing–Based Immune Signatures is Superior
Findings from a correlative analysis of the CALGB 40601 and PAMELA studies in patients with early HER2-positive breast cancer